Clinical

The findings suggest that circulating N-terminal pro-B-type natriuretic peptide and growth differentiation factor-15, both soluble biomarkers of cardiovascular disease (CVD), may be indicators of the course of myelodysplastic syndromes (MDS) and outcomes.

Outcomes in this new analysis were compared among children aged 6 to 11 years, all of whom had severe atopic dermatitis and were randomized to treatment with dupilumab or placebo for 16 weeks.

The current literature is lacking on outcomes among patients with comorbid chronic rhinosinusitis (CRS) and immunoglobulin deficiencies, especially for those who must use surgery to manage their CRS.

Bispecific antibodies or chimeric antigen receptor (CAR) T-cell therapies are both associated with an increased risk of infection for patients with multiple myeloma (MM), explained Hans Lee, MD, of The University of Texas MD Anderson Cancer Center.

A study that focused on children aged 5 to 12 years who lived in the United States found no difference between atropine 0.01% and placebo in treating myopia progression.

With their final thoughts, the panelists emphasize patient-centered care is at the forefront of critical MS treatment considerations for providers.

A comprehensive look into MS treatment objectives is provided.

Some of the results with biologics and Janus kinase (JAK) inhibitors for atopic dermatitis have been better in practice compared with clinical trials, said Emma Guttman-Yassky, MD, PhD, FAAD, of the Icahn School of Medicine at Mount Sinai.

Patients with small cell lung cancer (SCLC) with fewer than 5 brain metastases fared better than those with more than 5 when treated with stereotactic radiosurgery (SRS).

With this study, investigators hoped to advance their understanding of cellulitis-mimicking reactions among patients currently receiving chemotherapy.

The findings come amidst growing use of the treatment approach.

Findings from the 5-year follow-up analysis of the phase 3 KEYNOTE-042 study continue to support frontline pembrolizumab as standard of care for PD-L1-positive, locally advanced/metastatic non–small cell lung cancer (NSCLC).

A new review article illuminates why physicians should keep coagulation disorders in mind when evaluating patients with heavy abnormal uterine bleeding.

Researchers conducted a voluntary surveillance program in a Kansas City, Missouri, school district to detect the prevalence of respiratory viruses among students and staff members.

The occurrence of treatment-related myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) after autologous hematopoietic cell transplantation (HCT) for multiple myeloma was associated with aggressive disease characteristics and poor outcomes.

Microbiome traits are likely regulated by trichostatin A, nuclear factor-κB, and CCAAT/enhancer-binding protein (CEBP) in asthma exacerbations, a new study suggests

A real-world study of 5 European countries shows frequent misdiagnoses/delays in diagnosis, acute hospitalizations, and quality-of-life impairments.

An online survey identified that documentation requirements and communication issues with health plans are associated with providers modifying clinical decisions to avoid medication prior authorization.

Few validated measures exist to quantify sleep disturbance among patients who have the chronic inflammatory skin condition prurigo nodularis.

Researchers summarized the limited available data on human papillomavirus (HPV) vaccine efficiency and immunogenicity in people living with HIV and gave insight into topics for further research.

Panelists reached a consensus on statements about chronic cough diagnosis, helping to solidify opinions that can assist in the future creation of assessment guidelines.

More than 4 in 10 participants received a rare disease diagnosis as a result of the analysis.

Panelists provide their closing thoughts on optimizing the management of HIV.

The panel of experts discusses emerging and anticipated changes to the HIV treatment landscape.

Chimeric antigen receptor T-cell therapies are already moving into earlier lines of therapy for patients with diffuse large B-cell lymphoma (DLBCL), and now people are looking at when to use bispecific antibodies.